Thisstudywasconductedonfifiyuremicpatientsunderregularhaemodialysisand10healthycontrolsubjectsinordertostudytheparametersofironstatusandserumaluminuminthesepatients,andtoellucidatetheefiectofdifferentmodalitiesoftreatmentontheanemia,iron
statusparametersandserumaluminum,
Theuremicpatientswereclassifiedintofivegroups,eachincluded10 i
patients:groupIpatientsdidn'treceivetreatment,group11patientswas
givenTHLLEPO.groupIIIpatientswasgivenoraliron,groupIVpatientsreceivedcorrdvinedEPOandiron,whereasgroupVpatientsreceiveddesferroxamine.Thedurationoftreatmentwas6months.Thefollowinginvestigations, were performed before and after treatment: complete
bloodpicture,bloodurea,serumcreatinine,serumferritin,serumiron,total
ironbindingcapacity,ironbindingsaturation,serumaluminumandbone E
marrow(B.M)biopsy.
Ourstudyshowedthatanemiawasauniversalfindinginalluremic
patients60%hadmicrocytichypochromicand40%hadnormocyticnormochromicanemia.
SerumFe,TIBC,IBSandBMironstorageweresignificantlylowin
uremicpatients,whereasserumferritinandserumaluminumlevelswere
significantlyhighinthesepatients. |
